Shield Therapeutics (LON:STX) Stock Price Down 23.5% – Time to Sell?

Shield Therapeutics plc (LON:STX)’s stock price was down 23.5% during mid-day trading on Thursday . The stock traded as low as GBX 4.25 and last traded at GBX 4.40. Approximately 24,498,359 shares changed hands during mid-day trading, an increase of 1,091% from the average daily volume of 2,056,888 shares. The stock had previously closed at GBX 5.75.

Shield Therapeutics Trading Down 23.5%

The stock has a 50-day moving average of GBX 6.14 and a 200 day moving average of GBX 8.07. The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87. The stock has a market cap of £47.06 million, a PE ratio of -2.20 and a beta of 1.76.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.